BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19549100)

  • 1. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Kumar V; Ghosh B; Raina UK; Goel N
    Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
    [No Abstract]   [Full Text] [Related]  

  • 2. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
    Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
    Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Fang X; Sakaguchi H; Gomi F; Oshima Y; Sawa M; Tsujikawa M; Ikuno Y; Kamei M; Kusaka S; Tano Y
    Acta Ophthalmol; 2008 Nov; 86(7):800-5. PubMed ID: 18547274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
    Ozkiriş A
    Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correspondence.
    Rajpal S; Narula R; Agarwal M; Chaudhary SP
    Retina; 2010; 30(7):1160; author reply 1160. PubMed ID: 20616693
    [No Abstract]   [Full Text] [Related]  

  • 8. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME).
    Querques G
    Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285
    [No Abstract]   [Full Text] [Related]  

  • 9. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract.
    Akinci A; Batman C; Ozkilic E; Altinsoy A
    Retina; 2009; 29(10):1432-5. PubMed ID: 19898181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study.
    Szaflik JP; Szaflik J
    Retina; 2010 Sep; 30(8):1328-9; author reply 1329. PubMed ID: 20827155
    [No Abstract]   [Full Text] [Related]  

  • 12. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
    Michaelides M; Kaines A; Hamilton RD; Fraser-Bell S; Rajendram R; Quhill F; Boos CJ; Xing W; Egan C; Peto T; Bunce C; Leslie RD; Hykin PG
    Ophthalmology; 2010 Jun; 117(6):1078-1086.e2. PubMed ID: 20416952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.
    Saito W; Kase S; Ohgami K; Mori S; Ohno S
    Acta Ophthalmol; 2010 May; 88(3):377-80. PubMed ID: 18778334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
    Takamura Y; Kubo E; Akagi Y
    Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema.
    Chung EJ; Roh MI; Kwon OW; Koh HJ
    Retina; 2008; 28(7):957-63. PubMed ID: 18698297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolution of diabetic papillopathy after a single intravitreal injection of ranibizumab.
    Willerslev A; Munch IC; Larsen M
    Acta Ophthalmol; 2012 Aug; 90(5):e407-9. PubMed ID: 22268957
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
    Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
    Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.